Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchNitric OxideNitric Oxide (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Nitric Oxide for COVID-19: real-time meta analysis of 11 studies

@CovidAnalysis, May 2024, Version 11V11
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Winchester (DB RCT) 42% 0.58 [0.36-0.94] no improv. 8/15 23/25 Improvement, RR [CI] Treatment Control Winchester (DB RCT) 51% 0.49 [0.32-0.75] viral load 40 (n) 40 (n) Tandon (DB RCT) 68% 0.32 [0.09-1.12] no improv. 3/64 10/69 Tandon (DB RCT) 67% 0.33 [0.11-0.97] no improv. 4/64 13/69 Tandon (DB RCT) 42% 0.58 [0.33-1.01] no improv. 14/64 26/69 Tandon (DB RCT) 22% 0.78 [0.32-1.89] no improv. 8/105 10/102 Tandon (DB RCT) 18% 0.82 [0.39-1.75] no improv. 11/105 13/102 Tandon (DB RCT) 9% 0.91 [0.60-1.38] no improv. 30/105 32/102 Tandon (DB RCT) 20% 0.80 [0.75-0.86] viral load 64 (n) 69 (n) Tandon (DB RCT) 14% 0.86 [0.83-0.90] viral load 105 (n) 102 (n) Tandon (DB RCT) 26% 0.74 [0.52-1.05] viral time 64 (n) 69 (n) Tandon (DB RCT) 6% 0.94 [0.70-1.25] viral time 105 (n) 102 (n) Bryan (DB RCT) -1% 1.01 [0.21-4.95] progression 3/261 3/263 Bryan (DB RCT) 11% 0.89 [0.71-1.11] recov. time 261 (n) 263 (n) Chandel -54% 1.54 [0.72-2.78] death 12/66 36/206 Chandel -27% 1.27 [0.82-1.73] ventilation 29/66 79/206 Moni (RCT) 90% 0.10 [0.01-0.76] death 0/14 4/11 ICU patients Moni (RCT) 90% 0.10 [0.01-0.76] ventilation 0/14 4/11 ICU patients Moni (RCT) 42% 0.58 [0.05-1.00] no improv. 3/14 7/11 ICU patients Moni (RCT) 64% 0.36 [0.17-0.74] viral load 14 (n) 11 (n) ICU patients Moni (RCT) 63% 0.37 [0.18-0.75] viral load 14 (n) 11 (n) ICU patients Strickland (RCT) -179% 2.79 [0.12-64.0] ventilation 1/19 0/15 Strickland (RCT) 21% 0.79 [0.05-11.6] hosp. 1/19 1/15 Strickland (RCT) -38% 1.38 [0.50-3.85] misc. 7/19 4/15 Poonam 14% 0.86 [0.72-1.04] death 32/41 56/62 Ventilated patients OT​1​ Valsecchi 58% 0.42 [0.02-9.86] death 0/20 1/51 Valsecchi 68% 0.32 [0.08-1.26] ventilation 2/20 16/51 Valsecchi 39% 0.61 [0.27-1.39] ICU 5/20 21/51 Al Sulaiman (ICU) -40% 1.40 [0.94-2.11] death 44/56 52/125 ICU patients Al Sulaiman (ICU) -18% 1.18 [0.77-1.82] death 41/56 44/122 ICU patients Di Fenza (SB RCT) 23% 0.77 [0.44-1.32] death 94 (n) 99 (n) Ventilated patients Di Fenza (SB RCT) 26% 0.74 [0.39-1.40] death 94 (n) 99 (n) Ventilated patients Di Fenza (SB RCT) 13% 0.87 [0.52-1.43] death 94 (n) 99 (n) Ventilated patients Di Fenza (SB RCT) 15% 0.85 [0.50-1.46] death 94 (n) 99 (n) Ventilated patients Di Fenza (SB RCT) 30% 0.70 [0.14-3.39] progression 94 (n) 99 (n) Ventilated patients Di Fenza (SB RCT) 83% 0.17 [0.04-0.62] misc. 94 (n) 99 (n) Ventilated patients SaNOtize 75% 0.25 [0.14-0.43] cases 13/203 108/422 Nitric oxide COVID-19 outcomes c19early.org May 2024 ​1​ OT: comparison with other treatment Favors nitric oxide Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit